期刊文献+

人附睾蛋白4在卵巢癌诊断中应用研究 被引量:7

Application of human epididymis protein 4 in diagnosis of ovarian carcinoma
原文传递
导出
摘要 目的探讨人附睾蛋白4(human epididymis protein 4,HE4)在卵巢癌诊断中的价值。方法采用ELISA法检测62例卵巢癌患者(卵巢癌组)、38例卵巢良性肿瘤患者(卵巢良性肿瘤组)及100例体检健康者(对照组)血清HE4水平,并与CA125试剂盒检测结果进行比较分析。结果卵巢癌组血清HE4水平((443.33±244.59)pmol/L)明显高于卵巢良性肿瘤组((113.18±79.95)pmol/L)和对照组((72.52±42.45)pmol/L),差异均有统计学意义(P<0.01);HE4诊断卵巢癌较CA125有更高的敏感度和特异性,且二者一致性较好(Kappa=0.708),HE4和CA125联合检测的敏感度和特异性分别为91.94%和92.03%,较单一标志物的检测更具优势。结论血清中HE4水平对卵巢癌具有较高诊断价值,是诊断卵巢癌新的血清标志物之一。 Objective To discuss the diagnostic value of human epididymis protein 4. (HE4) level to ovarian carcinoma o{ gynecology. Methods The HE4 level was detected with ELISA technique in 62 cases of pelvic ovarian cancer (ovarian carcinoma group), 38 cases of benign ovarian tumors (benign ovarian tumor group), and 100 cases of healthy women (control group), which was compared with the result of CA125 kit. Results The serum HE4 level was significantly higher in ovarian carcinoma group ((443. 33 ± 244. 59)pmol/L) than that in ovarian benign tumor group ((113. 18 ± 79.95)pmol/L) and control group ((72.52±42.45)pmol/L) (P〈0.01). HE4 had higher sensitivity and specificity than CA125, and also had good agreement with CA125 (Kappa 0. 708). With 91. 94% of sensitivity and 92. 03% of specificity, the joint detection of HE4 and CA125 was more superior to the single detection of HE4 or CA125. Conclusion Being one of new markers of the diagnosis of ovarian cancer, HE4 level has a high diagnostic value to ovarian carcinoma.
出处 《中华实用诊断与治疗杂志》 2013年第2期153-154,共2页 Journal of Chinese Practical Diagnosis and Therapy
关键词 卵巢癌 人附睾蛋白4 诊断 应用 Ovarian carcinoma human epididymis protein 4 diagnosis application
  • 相关文献

参考文献11

  • 1杨国奋,李晓明,谢丹,朝葵,蔡鹏宇.卵巢癌组织中clusterin蛋白表达和细胞凋亡检测[J].中国肿瘤临床,2007,34(12):674-676. 被引量:17
  • 2Hellstrom I,Raycraft J,Hayden-Ledbetter M. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma[J].Cancer Research,2003,(13):3695-3700.
  • 3Drapkin R,Vonhorsten H H,Lin Y. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas[J].Cancer Research,2005,(11):2162-2169.doi:10.1158/0008-5472.CAN-04-3924.
  • 4Moore R G,Brown A K,Miller M C. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J].Gynecologic Oncology,2008,(02):402-408.doi:10.1016/j.ygyno.2007.10.017.
  • 5Moore R G,McMeekin D S,Brown A K. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J].Gynecologic Oncology,2009,(01):40-46.doi:10.1016/j.ygyno.2008.08.031.
  • 6Kirchhof C,Habben I,Ivell R. A major human epididymis specific cdna encodes a protein with sequence homology to extraeellular proteinase inhibitors[J].Biology of Reproduction,1991,(02):350-357.
  • 7Lu K H,Patterson A P,Wang L. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis[J].Clinical Cancer Research,2004,(10):3291-3300.
  • 8Shah C A,Lowe K A,Paley P. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin,HE4,and CA125[J].Cancer Epidemiology Biomarkers and Prevention,2009,(05):1365-1372.
  • 9Anastasi E,Marchei G G,Viggiani V. HE4:a new potential early biomarker for the recurrence of ovarian cancer[J].Tumour Biology,2010,(02):113-119.doi:10.1007/s13277-009-0015-y.
  • 10王锋,廖予妹,王武亮,黄冬梅,樊冬梅.血清人附睾分泌蛋白4、癌胚抗原125联合检测诊断卵巢上皮性癌的价值[J].中华实用诊断与治疗杂志,2010,24(4):383-384. 被引量:8

二级参考文献33

共引文献47

同被引文献61

  • 1沈铿.复发性卵巢癌的诊断和治疗策略[J].现代妇产科进展,2005,14(3):177-180. 被引量:35
  • 2汤洁,蔡树模,黄啸,李子庭,臧荣余.复发性卵巢癌的化放疗研究[J].肿瘤,2007,27(8):638-641. 被引量:8
  • 3Moore R G, McMeekin D S, Brown A K, et a]. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J]. Gynecol Oncol,2009,112(1) :40-46.
  • 4Gadducci A, Cosio S, Carpi A, et al. Serum tumor markers in the management of ovarian, endometrial and cervical cancer[J]. Biomed Pharmacother, 2004,58 (1) : 24-38.
  • 5Kim H S, Park N H, Chung H H, et al. Serum CA125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian caneer[J]. Onkologie, 2008,31 (6) :315 -320.
  • 6Hellstrom I, Raycraft J, Hayden-Ledbetter M, et aZ. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma [J]. Cancer Res,2003,63(13) :3695 -3700.
  • 7Gadducei A, Conte P, Cianci C, et al. Treatment options in patients with recurrent ovarian cancer [J]. Anticancer Res, 2001,21(5):3557- 3564.
  • 8Strauss H G, Henze A, Teichmann A, et al. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer[J]. Gynecol Oncol, 2007, 104(3):612- 616.
  • 9Rose P G. Gemcitabine reverses platinum resistance in platinum- resistant ovarian and peritoneal carcinoma [J]. Int J Gynecol Cancer,2005,15(1) : 18-22.
  • 10Wykosky J, Gibo D M, Stanton C, et al. EphA2 as a novel molecular marker and target in glioblastoma moltiform[J]. Mol Cancer Res,2005,3(10) :541-551.

引证文献7

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部